Litigation Details for Medicines Company v. Teva Parenteral Medicines Inc. (D. Del. 2009)

« Back to Dashboard

Medicines Company v. Teva Parenteral Medicines Inc. (D. Del. 2009)

Docket	1:09-cv-00999	Date Filed	2009-12-28
Court	District Court, D. Delaware	Date Terminated	2010-03-25
Cause	35:271 Patent Infringement	Assigned To	Eduardo C. Robreno
Jury Demand	Defendant	Referred To
Patents	7,582,727; 7,598,343
Link to Docket	External link to docket

Details for Medicines Company v. Teva Parenteral Medicines Inc. (D. Del. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-12-28				External link to document

The Medicines Company v. Teva Parenteral Medicines, Inc. Litigation Summary and Patent Analysis, 1:09-cv-00999

Last updated: October 9, 2026

The Medicines Company sued Teva Parenteral Medicines in the U.S. District Court for the District of Delaware after Teva filed an abbreviated new drug application seeking approval for a generic version of Angiomax, whose active ingredient is bivalirudin. The case centered on patents covering low-impurity bivalirudin compositions and their manufacturing processes, principally U.S. Patent Nos. 7,582,727 and 7,598,343. The dispute was part of a broader Angiomax patent campaign involving several generic-drug companies.

The public record indicates that the Teva matter was resolved without a reported merits judgment establishing that Teva infringed the asserted patents. The later Federal Circuit litigation involving Hospira materially affected the legal analysis of the same Angiomax patent family, particularly the validity of process claims under the on-sale bar.

What was The Medicines Company v. Teva about?

The case concerned Teva’s ANDA for a generic injectable bivalirudin product. The Medicines Company alleged that Teva’s proposed product and manufacturing activities would infringe patents listed for Angiomax.

Bivalirudin is a direct thrombin inhibitor administered by injection. Angiomax was approved by the FDA for use as an anticoagulant in connection with percutaneous coronary intervention and related cardiovascular procedures. The commercial product had a relatively narrow formulation profile, with patent protection focused less on a new chemical entity and more on product purity, impurity control, and manufacturing conditions.

The principal litigation issues were:

Issue	Relevance
ANDA filing	Created a Hatch-Waxman patent dispute and triggered a Paragraph IV litigation framework
Bivalirudin formulation	Concerned the composition and impurity profile of the proposed generic
Manufacturing process	Concerned processes for producing batches of bivalirudin with specified impurity levels
Patent validity	Included obviousness and statutory-bar issues
Infringement	Required analysis of Teva’s proposed product and manufacturing methods
Generic entry	Depended on patent resolution, FDA approval, and any settlement terms

The complaint was filed in the District of Delaware under Civil Action No. 1:09-cv-00999. The Medicines Company was the branded-product patent owner and Angiomax sponsor. Teva Parenteral Medicines was the ANDA applicant and proposed generic manufacturer.

What patents protected Angiomax in the Teva litigation?

The central patents were U.S. Patent Nos. 7,582,727 and 7,598,343. Both patents originated from The Medicines Company’s work on producing bivalirudin with controlled levels of impurities.

Patent	General subject matter	Relevance to Angiomax litigation
U.S. 7,582,727	Bivalirudin pharmaceutical batches and impurity control	Asserted against generic applicants, including in related litigation
U.S. 7,598,343	Related bivalirudin production and batch-processing claims	Part of the broader patent family and litigation strategy
U.S. 5,196,404	Earlier bivalirudin-related patent protection	Historic Angiomax protection; not the principal late-stage patent issue
U.S. 7,582,727 family continuations and related filings	Manufacturing and composition protection	Supported additional patent and regulatory coverage

The patents did not primarily protect bivalirudin as a new molecular entity. Their commercial value came from protecting a formulation and production method that reduced degradation products and other impurities. This type of patent estate can delay generic entry even after basic compound protection has expired, but its strength depends heavily on claim construction, proof of infringement, and the validity of the manufacturing claims.

What Paragraph IV challenge did Teva make?

Teva’s ANDA filing was treated as a Paragraph IV challenge to The Medicines Company’s listed patents. Under the Hatch-Waxman framework, a Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The filing allowed The Medicines Company to bring an infringement action before FDA approval. The litigation therefore created an automatic statutory stay of FDA approval for up to 30 months, subject to the statutory exceptions and the parties’ litigation conduct. The case was not a conventional post-launch patent dispute. It was an ANDA action intended to determine whether Teva could obtain approval and enter before expiration of the relevant patents.

The exact content of Teva’s non-infringement and invalidity positions is best evaluated against the patent claims and the ANDA’s confidential manufacturing information. Publicly reported materials indicate that the broader defense themes included:

• non-infringement based on the proposed product or process;
• invalidity based on prior art and statutory patent-bar arguments;
• challenges to the scope of claims directed to impurity levels and batch production; and
• potential limitations on applying process claims to an ANDA filing.

What was the court’s ruling in the Teva case?

The Teva case did not produce the type of widely cited final merits decision associated with the later Hospira litigation. The public record reflects resolution of the Teva dispute without a reported trial judgment that conclusively established infringement of the asserted patents by Teva.

That distinction matters. A dismissal or settlement in an ANDA case does not establish that the patents were valid, that Teva’s proposed product infringed, or that the branded company’s claim construction would have prevailed at trial. It generally establishes only that the parties ended the particular dispute on negotiated terms.

The Teva case should therefore be separated from later decisions addressing the same Angiomax patent family. Courts and analysts should not treat the outcome of the Teva docket as a binding merits determination unless the specific order or settlement agreement says otherwise.

How did The Medicines Company v. Hospira affect the Teva analysis?

The later Hospira litigation addressed the same general patent family and materially changed the risk assessment for Angiomax process patents.

In The Medicines Company v. Hospira, the Federal Circuit, sitting en banc, held that a commercial sale of a product made using a patented process can trigger the on-sale bar under 35 U.S.C. § 102(b), even when the transaction does not transfer the patented process itself. The court rejected the argument that a contract manufacturer’s sale of manufacturing services could avoid the statutory bar merely because the process was not separately sold. [1]

The Federal Circuit’s decision was important for U.S. Patent Nos. 7,582,727 and 7,598,343 because those patents claimed aspects of the process used to produce low-impurity bivalirudin batches. The decision increased invalidity risk for similar process claims based on pre-critical-date commercial activity.

The practical implications for the Teva dispute were:

1. Process-patent validity risk increased. The Medicines Company could not assume that undisclosed or indirect commercial activity was irrelevant to the on-sale bar.
2. Manufacturing evidence became central. Contract-manufacturing agreements, batch records, invoices, and supply arrangements could affect validity.
3. Product patents and process patents had different risk profiles. A generic applicant could challenge process claims without necessarily challenging every composition claim.
4. Settlement value became more fact-dependent. The strength of the branded company’s position depended on the exact claims, manufacturing route, and critical dates.

The en banc decision was not a direct adjudication of Teva’s liability. It was a later legal development relevant to the same patent family and to the validity theories that could arise in an ANDA case.

What was the FDA and Orange Book status of Angiomax?

Angiomax was FDA-approved as an injectable bivalirudin product. The FDA Orange Book listed patent information for the product, including patents associated with the formulation and manufacturing technology. Orange Book listing allowed The Medicines Company to invoke the Hatch-Waxman framework when generic applicants certified against the listed patents. [2]

The regulatory structure was as follows:

Regulatory item	Status
Reference product	Angiomax, bivalirudin for injection
Sponsor	The Medicines Company
FDA pathway for Teva	ANDA
Patent certification	Paragraph IV
Litigation venue	District of Delaware
Regulatory consequence	Statutory approval stay following timely patent litigation
Generic approval timing	Dependent on patent resolution, settlement terms, and FDA review

Orange Book listing does not mean that the FDA has determined a patent is valid or infringed. It is a regulatory notice mechanism. Patentability and infringement remained matters for the federal courts.

When did Angiomax lose exclusivity?

Angiomax’s exclusivity was layered rather than tied to one date. The earliest compound-related protection did not provide the same commercial barrier as the later patents directed to formulation and manufacturing.

The critical commercial issue was the expiration or resolution of later-listed patents, particularly those covering low-impurity bivalirudin batches. The patents were issued in 2009 and had nominal terms extending into the late 2020s, subject to patent-term adjustment, terminal disclaimers, and any applicable statutory corrections. The existence of a late-expiring patent did not itself guarantee market exclusivity because:

• claims could be invalidated;
• a generic applicant could avoid infringement;
• the parties could settle for an agreed launch date;
• the FDA could approve a generic after the relevant statutory stay ended; and
• separate patents could be found not to cover the approved generic product.

For commercial forecasting, the relevant date was the earliest legally permitted generic launch under the particular settlement or court outcome, not simply the latest listed patent expiration date.

What settlement terms were associated with the Teva case?

The public docket does not provide a reported merits ruling that fully discloses the economic and commercial terms of the Teva resolution. As in many ANDA cases, settlement provisions may have included a dismissal, a permitted-entry date, a covenant not to sue, or restrictions tied to patent validity and infringement.

A settlement should not be interpreted as proof that The Medicines Company defeated Teva. Nor does it establish that Teva’s Paragraph IV positions were legally correct. The commercial result depends on the agreed generic-entry date, whether the agreement included a license, and whether the settlement affected other generic applicants.

The absence of a reported public merits opinion limits the ability to quantify the precise value transferred between the parties or to determine whether Teva received an authorized-generic arrangement, a license, or another form of launch accommodation.

How strong was The Medicines Company’s Angiomax patent estate?

The patent estate was commercially meaningful but legally exposed.

Strengths

• The patents targeted a defined impurity profile and manufacturing result.
• The claims could reach production methods used by contract manufacturers.
• The patents were listed in the Orange Book, enabling Hatch-Waxman litigation.
• The estate extended beyond the original compound patent.
• The branded company could use multiple patents and multiple defendants to delay or coordinate generic entry.

Weaknesses

• Process claims faced on-sale-bar scrutiny.
• Infringement could depend on confidential ANDA manufacturing information.
• A generic could design around particular impurity thresholds or process limitations.
• The patents did not provide the same protection as an unexpired composition-of-matter patent.
• A settlement could permit entry before patent expiration.

The later Hospira decision reduced confidence in the durability of the process-patent strategy by confirming that prior commercial activity could invalidate claims under the on-sale bar. [1]

What generic entry risks existed for Angiomax?

The principal generic-entry risks were:

1. Paragraph IV litigation by multiple ANDA applicants. A favorable ruling for one applicant could weaken the broader patent position.
2. Invalidity based on pre-critical-date commercial activity. This risk was especially relevant to process patents.
3. Non-infringing manufacturing routes. Teva could seek FDA approval for a product made by a process outside the asserted claims.
4. Settlement-driven entry. The branded company could preserve some patent value while allowing generic entry before expiration.
5. Revenue erosion after approval. Injectable hospital products can experience rapid price pressure once multiple generic suppliers enter.
6. Limited value of Orange Book listing after claim weakness emerges. Listing creates procedural leverage but does not cure validity or infringement defects.

How does the Teva case compare with the Hospira case?

Factor	Teva litigation	Hospira litigation
Court	District of Delaware	District of Delaware, with Federal Circuit review
Product	Generic bivalirudin for injection	Generic bivalirudin for injection
Patent family	Angiomax low-impurity formulation/process patents	Same general patent family
Public merits ruling	No widely cited final merits determination	Federal Circuit en banc decision on on-sale bar
Core legal significance	ANDA challenge and negotiated resolution	Pre-critical-date commercial sale and patent validity
Commercial effect	Relevant to generic-entry timing	Reduced confidence in process-patent enforceability

Key Takeaways

• The Medicines Company v. Teva Parenteral Medicines, Inc., No. 1:09-cv-00999, was an ANDA patent case involving generic bivalirudin.
• The dispute focused on Angiomax patents covering low-impurity bivalirudin formulations and manufacturing processes.
• U.S. Patent Nos. 7,582,727 and 7,598,343 were central to the broader Angiomax patent program.
• The Teva matter did not produce a widely reported merits judgment establishing infringement.
• The later Hospira decision increased invalidity risk for the same type of process claims by applying the on-sale bar to commercial sales of products made using a patented process.
• Orange Book listing created Hatch-Waxman litigation leverage but did not establish patent validity.
• Generic entry depended on the litigation resolution, any settlement license, FDA approval, and the scope of the proposed manufacturing process.
• The Angiomax estate was commercially effective but weaker than an unexpired composition-of-matter patent because its key claims depended on formulation details, process evidence, and validity defenses.

FAQs About The Medicines Company v. Teva Parenteral Medicines

Did Teva receive FDA approval for generic Angiomax?

Teva pursued FDA approval through an ANDA, but the litigation docket alone does not establish the precise date or terms of any eventual FDA approval or commercial launch.

Did the Teva case invalidate Angiomax patents?

No reported Teva merits decision establishes that the asserted Angiomax patents were invalid. The later Hospira litigation separately raised substantial validity issues for related process claims.

Which drug was challenged in the case?

The challenged reference product was Angiomax, an injectable bivalirudin product sponsored by The Medicines Company.

Did the case involve biosimilar litigation?

No. Bivalirudin is a chemically synthesized drug, and the dispute proceeded under the generic-drug ANDA pathway rather than the biologic biosimilar pathway.

Did the case affect Angiomax revenue?

The litigation created uncertainty over the timing of generic competition. Actual revenue impact depended on the settlement or dismissal terms, the timing of FDA approval, and the number of generic manufacturers entering the market.

References

1. The Medicines Co. v. Hospira, Inc., 827 F.3d 1363 (Fed. Cir. 2016) (en banc).

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. The Medicines Co. v. Teva Parenteral Medicines, Inc., No. 1:09-cv-00999 (D. Del. filed Oct. 20, 2009).

4. U.S. Patent No. 7,582,727. (2009). Pharmaceutical batches of bivalirudin.

5. U.S. Patent No. 7,598,343. (2009). Pharmaceutical batches of bivalirudin.